{"analyses":[{"ciLowerLimit":"0.36","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.79","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0015","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable as not enough events had occurred at the time of the data cut-off date","groupId":"OG000","lowerLimit":"22.9","upperLimit":"NA","value":"36.6"},{"groupId":"OG001","lowerLimit":"12.8","upperLimit":"27.6","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab 375 mg/m\\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \\< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.","id":"OG000","title":"Rituximab + Lenalidomide (R^2)"},{"description":"Participants received rituximab 375 mg/m\\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up to 12 cycles.","id":"OG001","title":"Rituximab + Placebo"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved an objective response in the ITT population.","reportingStatus":"POSTED","timeFrame":"From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).","title":"Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC","type":"SECONDARY","unitOfMeasure":"months"}